Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864248 | 0.78 | CPB2 (0.36) | PARP1 | |
| SCHEMBL14335666 | 0.78 | ALDH1A1 (0.35) | ALDH1A1PARP1 | |
| SCHEMBL20083747 | 0.78 | PIK3CA (0.34) | ALDH1A1PARP1CHRNB2CHRNA4PIK3CA | |
| SCHEMBL29436325 | 0.77 | ALDH1A1 (0.46) | ALDH1A1NPSR1S1PR4MAPT | |
| SCHEMBL116316 | 0.77 | ALDH1A1 (0.46) | ALDH1A1NPSR1S1PR4MAPT | |
| SCHEMBL30375869 | 0.74 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL29768993 | 0.74 | LMNA (0.38) | ALDH1A1MAPTPIK3CA | |
| SCHEMBL1008622 | 0.74 | ALDH1A1 (0.41) | ALDH1A1PARP1 | |
| SCHEMBL27392980 | 0.74 | LMNA (0.38) | ALDH1A1MAPTPIK3CA | |
| SCHEMBL13859010 | 0.72 | ALDH1A1 (0.46) | ALDH1A1NPSR1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132600-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132600-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | ALDH1A1 797/4885NPSR1 119/4885S1PR4 557/4885 |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | ALDH1A1 797/4885NPSR1 119/4885S1PR4 557/4885 |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | ALDH1A1 797/4885NPSR1 119/4885S1PR4 557/4885 |
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | TRPV1, TRPA1, TRPV5 | ALDH1A1 797/4885NPSR1 119/4885S1PR4 557/4885 |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | ALDH1A1 1041/4885NPSR1 86/4885S1PR4 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.